Last updated on July 2019

Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome


Brief description of study

This study will evaluate the efficacy and safety of vibegron, a beta-3 adrenergic receptor (3-AR) agonist, in the treatment of pain associated with irritable bowel syndrome (IBS) due to IBS with predominant diarrhea (IBS-D) or mixed episodes of diarrhea and constipation (IBS-M).

Clinical Study Identifier: NCT03806127

Find a site near you

Start Over